除了擴(kuò)大專著量取得產(chǎn)品制定的許可證，公司還支持對(duì)于草藥和補(bǔ)充藥品領(lǐng)域的監(jiān)管工作，
通過為傳統(tǒng)草藥產(chǎn)品、順勢(shì)療法藥品的存貨和母酊劑提供新專著。BP也已開始提高未經(jīng)許可藥品的質(zhì)量，為廣泛使用的無證藥物、未經(jīng)授權(quán)的配方提供標(biāo)準(zhǔn)品連同更多的法律上和道德上的指導(dǎo)和這些產(chǎn)品的補(bǔ)充。
BP與歐洲藥典的工作保持密切聯(lián)系,將繼續(xù)扮演在歐洲標(biāo)準(zhǔn)制定過程的重要角色，積極參與歐洲理事會(huì)藥品質(zhì)量和衛(wèi)生保健的活動(dòng), 通過英國代表團(tuán)影響歐洲藥典委員會(huì)的決策。歐洲藥典的文本和專著是BP的組成部分。
經(jīng)過每年的不斷更新,BP是唯一可以向英國藥用物質(zhì)提供綜合性標(biāo)準(zhǔn)品的。這對(duì)于所有參與醫(yī)藥研究、開發(fā)、制造、質(zhì)量控制的個(gè)人和機(jī)構(gòu)和分析都是很重要的。
自首次出版之后，BP的發(fā)展已經(jīng)遍布全世界?，F(xiàn)在五大洲中接近100個(gè)國家都在使用BP的產(chǎn)品，BP正在為全球的制藥合規(guī)設(shè)立一系列的標(biāo)準(zhǔn)。英國周邊的國家只有澳大利亞和加拿大這兩個(gè)國家采用了BP的標(biāo)準(zhǔn)作為他們的國家標(biāo)準(zhǔn)。
Since 1864, the British Pharmacopoeia (BP) has been providing authoritative official standards for pharmaceutical substances and medicinal products. It makes an important contribution to the role of the Medicines and Healthcare products Regulatory Agency in protecting public health by setting publicly available standards for the quality of medicines.
In addition to expanding the numbers of monographs for licensed formulated products, it supports the regulatory work in the fields of herbal and complementary medicines by providing new monographs for traditional herbal medicinal products and for homoeopathic stocks and mother tinctures. The BP has also begun to improve the control of the quality of unlicensed medicines by providing standards for extensively used unlicensed formulations together with further legal and ethical guidance on the preparation and supply of these products.
The British Pharmacopoeia maintains close ties with the work of the European Pharmacopoeia and continues to play a significant role in the standard-setting process in Europe, participating in the activities of the European Directorate for the Quality of Medicines and Healthcare, and influencing the decisions of the European Pharmacopoeia Commission through the United Kingdom Delegation. The texts and monographs of the European Pharmacopoeia form an integral part of the BP.
Annually updated, the British Pharmacopoeia is the only comprehensive collection of standards for UK medicinal substances. It is essential for all individuals and organisations involved in pharmaceutical research, development, manufacture, quality control and analysis.
Since its first publication the distribution of the British Pharmacopoeia has grown throughout the world. Now used in approaching 100 countries with exposure in most continents of the world, the BP is setting the standard for pharmaceutical compliance across the globe. Australia and Canada are just two of the countries that have adopted the BP as their national standard alongside the UK.
